Contribute Try STAT+ Today

WASHINGTON — In one of their first acts of 2020, state lawmakers will attempt to bring a vanquished bill back from the dead.

Lawmakers in New Hampshire next month are set to consider a proposed ban on generic drug “price gouging” — the latest in a series of attempts by statehouses to tackle prescription drug costs. But as most state legislatures around the country pursue new, aggressive ideas to lower drug prices, the Granite State is revisiting a bill largely left for dead after a federal court struck down Maryland’s version two years ago.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.